Partow Kebriaei
#162,640
Most Influential Person Now
Researcher
Partow Kebriaei's AcademicInfluence.com Rankings
Partow Kebriaeicomputer-science Degrees
Computer Science
#9485
World Rank
#9959
Historical Rank
Machine Learning
#4161
World Rank
#4210
Historical Rank
Artificial Intelligence
#4505
World Rank
#4567
Historical Rank
Database
#6449
World Rank
#6682
Historical Rank
Download Badge
Computer Science
Partow Kebriaei's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science Stanford University
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Partow Kebriaei Influential?
(Suggest an Edit or Addition)Partow Kebriaei's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities (2018) (1415)
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. (2020) (881)
- Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. (1995) (781)
- Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. (2013) (454)
- Cord-blood engraftment with ex vivo mesenchymal-cell coculture. (2012) (446)
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. (2012) (434)
- Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. (2009) (408)
- Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. (2012) (374)
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. (2016) (361)
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. (2010) (322)
- Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells (2016) (271)
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia (2013) (261)
- Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. (2013) (232)
- Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. (2012) (218)
- Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. (2014) (195)
- Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemia (2009) (195)
- Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. (2013) (189)
- Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. (2011) (181)
- Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD (2010) (170)
- Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells (2013) (163)
- Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (2015) (158)
- Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. (2016) (154)
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy (2018) (152)
- Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. (2009) (151)
- Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. (2017) (145)
- piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. (2010) (138)
- Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. (2015) (123)
- US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. (2016) (122)
- A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19 (2014) (121)
- Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial (2017) (114)
- Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. (2007) (109)
- Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. (2012) (106)
- Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma (2009) (103)
- Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' (2018) (100)
- Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. (2011) (99)
- Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease (2013) (97)
- Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia (2016) (96)
- Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. (2012) (93)
- Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. (2011) (91)
- Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. (2011) (89)
- Sleeping Beauty System to Redirect T-cell Specificity for Human Applications (2013) (85)
- Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage (2018) (82)
- Treatment of graft-versus-host-disease with mesenchymal stromal cells. (2011) (82)
- Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells (2015) (80)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. (2019) (80)
- Management of important adverse events associated with inotuzumab ozogamicin: expert panel review (2018) (80)
- Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. (2009) (80)
- New and emerging therapies for acute and chronic graft versus host disease (2018) (79)
- Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors (2014) (78)
- Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome (2009) (75)
- A Phase 3 randomized study of Remestemcel-L versus placebo added to second line therapy in patients with steroid refractory acute graft versus host disease. (2020) (75)
- Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. (2020) (75)
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) (74)
- Gene Therapy with the Sleeping Beauty Transposon System. (2017) (74)
- Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia (2017) (71)
- Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. (2011) (70)
- Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. (2012) (69)
- Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (2019) (66)
- Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. (2013) (66)
- Results of a 2‐arm, phase 2 clinical trial using post‐transplantation cyclophosphamide for the prevention of graft‐versus‐host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation (2016) (65)
- Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. (2011) (65)
- Acute lymphoblastic leukaemia: diagnosis and classification. (2002) (64)
- Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. (2015) (61)
- Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. (2009) (61)
- Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma (2018) (61)
- Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. (2017) (59)
- Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma (2021) (59)
- Biphenotypic acute leukaemia: a case series (2007) (59)
- Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT (2010) (57)
- Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. (2019) (57)
- Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. (2013) (56)
- Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. (2013) (56)
- Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. (2014) (56)
- Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood (2013) (56)
- Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia (2007) (56)
- Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation (2007) (54)
- Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. (2017) (54)
- Incidence and natural history of pure red cell aplasia in major ABO‐mismatched haematopoietic cell transplantation (2013) (54)
- Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes (2005) (53)
- Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. (2016) (53)
- Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. (2009) (53)
- Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. (2019) (53)
- Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. (2018) (52)
- Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. (2016) (52)
- The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. (2014) (52)
- Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome (2008) (50)
- Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma (2020) (50)
- Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease (2017) (50)
- Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. (2019) (50)
- Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. (2017) (49)
- Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. (2010) (49)
- Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. (2017) (48)
- Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients (2016) (47)
- Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia (2017) (47)
- Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation (2013) (47)
- Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia (2014) (47)
- Fixed‐dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma (2006) (45)
- Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. (2018) (45)
- Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma (2007) (44)
- Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. (2019) (44)
- Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. (2007) (44)
- Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation (2017) (44)
- High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. (2012) (43)
- High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. (2008) (43)
- Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. (2020) (43)
- Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. (2007) (43)
- Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice (2014) (41)
- Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. (2011) (40)
- Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. (2014) (40)
- Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia (2013) (39)
- Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia (2006) (38)
- Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. (2012) (37)
- Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. (2015) (35)
- Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. (2014) (35)
- Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts (2015) (35)
- High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. (2013) (35)
- Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. (2019) (34)
- Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. (2010) (34)
- Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes (2017) (34)
- Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. (2014) (34)
- MSCs in hematopoietic cell transplantation. (2011) (32)
- Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. (2020) (32)
- Better allele-level matching improves transplant-related mortality after double cord blood transplantation (2015) (32)
- Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. (2014) (32)
- Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? (2015) (32)
- Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. (2017) (30)
- Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. (2015) (30)
- CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. (2021) (30)
- Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions (2020) (29)
- Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. (2013) (29)
- Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients (2018) (29)
- Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. (2020) (29)
- Molecular Cloning Reveals Alternative Splice Forms of Human α(E)-Catenin (1994) (28)
- Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation (2015) (28)
- Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR (2012) (28)
- Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B‐cell lymphoma treated with autologous stem cell transplantation (2008) (27)
- Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation (2018) (27)
- Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. (2013) (27)
- Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. (2015) (26)
- A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells (2010) (26)
- Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma (2016) (26)
- Umbilical cord blood graft engineering: challenges and opportunities (2015) (26)
- Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. (2015) (25)
- High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation (2011) (24)
- Just‐in‐time rescue plerixafor in combination with chemotherapy and granulocyte‐colony stimulating factor for peripheral blood progenitor cell mobilization (2013) (24)
- Philadelphia chromosome-positive acute lymphoblastic leukemia. (2009) (24)
- Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils (2010) (24)
- Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL). (2006) (23)
- Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor (2014) (23)
- Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci. (2011) (23)
- Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome (2018) (23)
- Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma (2016) (22)
- Mesenchymal Stem Cell Therapy in the Treatment of Acute and Chronic Graft Versus Host Disease (2011) (22)
- Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia (2021) (22)
- Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. (2017) (22)
- Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer (2021) (22)
- The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. (2014) (22)
- Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL) (2012) (20)
- Is a matched unrelated donor search needed for all allogeneic transplant candidates? (2018) (20)
- Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. (2018) (20)
- CARs in Chronic Lymphocytic Leukemia – Ready to Drive (2013) (20)
- Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors (2019) (20)
- Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (2021) (20)
- Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. (2013) (20)
- Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors (2021) (20)
- Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant (2012) (19)
- Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). (2009) (19)
- Progress and challenges in the therapy of adult acute lymphoblastic leukemia (2003) (19)
- Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial (2018) (19)
- Comprehensive craniospinal radiation for controlling central nervous system leukemia. (2014) (19)
- Combination Immunotherapy with NY-ESO-1-Specific CAR+ T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect (2016) (18)
- Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. (2017) (18)
- Therapy‐related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens (2009) (18)
- Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) (2008) (18)
- Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB) (2008) (17)
- Chimeric antigen receptor T‐cell therapy toxicities (2020) (17)
- Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. (2011) (17)
- Evaluation and management of BK virus-associated nephropathy following allogeneic hematopoietic cell transplantation. (2011) (16)
- Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. (2009) (16)
- Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia (2021) (16)
- Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation (2019) (16)
- Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. (2021) (16)
- Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL (2013) (15)
- A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. (2013) (15)
- The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia (2012) (15)
- Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT. (2019) (15)
- An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia (2021) (15)
- Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. (2017) (15)
- Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (2019) (14)
- Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60 (2015) (14)
- Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL (2020) (14)
- Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD (2021) (14)
- Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning (2017) (14)
- Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies (2015) (14)
- A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma (2015) (14)
- Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. (2018) (14)
- Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB). (2007) (14)
- Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia (2016) (14)
- Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia (2021) (13)
- Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. (2021) (13)
- Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. (2020) (13)
- Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation (2021) (13)
- Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. (2018) (13)
- Bayesian Continual Reassessment Method for Dose-Finding Trials Infusing T Cells with Limited Sample Size (2012) (13)
- High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse (2022) (12)
- Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. (2013) (12)
- Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis (2017) (12)
- Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. (2013) (12)
- A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation. (2019) (12)
- Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2021) (12)
- Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. (2019) (12)
- Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products (2008) (12)
- Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. (2016) (12)
- Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. (2017) (12)
- Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma (2015) (12)
- Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. (2018) (11)
- Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse (2019) (11)
- Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial (2015) (11)
- Long-term outcomes of Sleeping Beauty generated CD19specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. (2020) (11)
- Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment (2013) (11)
- Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. (2021) (11)
- Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. (2008) (11)
- Patient-reported symptom and functioning status during the first 12 months after CAR T-cell therapy for hematological malignancies. (2021) (11)
- Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients (2017) (11)
- Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB). (2009) (11)
- Stem cell transplantation outcomes in lymphoblastic lymphoma (2017) (10)
- Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit (2015) (10)
- Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome. (2007) (10)
- Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. (2021) (10)
- Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. (2022) (10)
- Improved detection of sinusoidal obstructive syndrome using pediatric–AYA diagnostic criteria and severity grading (2020) (10)
- Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation (2016) (9)
- Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. (2012) (9)
- Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide (2021) (9)
- Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years (2019) (9)
- Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial (2018) (9)
- Long‐term follow‐up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T‐cell chimerism is associated with high relapse risk and inferior survival (2017) (9)
- Molecular cloning reveals alternative splice forms of human alpha(E)-catenin. (1994) (9)
- HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. (2019) (9)
- Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma (2017) (9)
- Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults (2014) (9)
- Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma (2015) (9)
- Low rate of infusional toxicity after expanded cord blood transplantation. (2014) (9)
- A randomized phase II study of standard‐dose versus high‐dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B‐cell non‐hodgkin lymphomas: long term results (2017) (8)
- Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease (2017) (8)
- Age is no Barrier for Adults undergoing HCT for AML in CR1: Contemporary CIBMTR Analysis (2022) (8)
- Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. (2020) (8)
- Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD). (2006) (8)
- Is there an expiration date for a cord blood unit in storage? (2014) (8)
- CARs: Driving T-cell specificity to enhance anti-tumor immunity (2012) (8)
- Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury (2016) (8)
- An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (2021) (8)
- A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia (2018) (8)
- Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center (2014) (8)
- Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. (2017) (8)
- Shortening the Time to Manufacture CAR+ T Cells with Sleeping Beauty System Supports T-Cell Engraftment and Anti-Tumor Effects in Patients with Refractory CD19+ Tumors (2017) (8)
- Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation (2020) (7)
- Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation (2019) (7)
- Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial (2016) (7)
- Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant (2018) (7)
- Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors? (2020) (7)
- A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids (2015) (7)
- A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd (2012) (7)
- Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. (2019) (7)
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS. (2004) (7)
- Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation (2021) (7)
- Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. (2020) (7)
- Endpoints for Clinical Trials Testing Treatment of Acute Graft- versus-host Disease: A Consensus Document (2010) (7)
- Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): The University of Texas M. D. Anderson Cancer Center (MDACC) experience. (2011) (7)
- Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy (2022) (7)
- Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT) (2011) (7)
- Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL) (2011) (7)
- Future of Therapy in Acute Lymphoblastic Leukemia (ALL)—Potential Role of Immune-Based Therapies (2015) (7)
- The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. (2021) (6)
- Manifestations and management of veno-occlusive disease/sinusoidal obstruction syndrome in the era of contemporary therapies. (2017) (6)
- Outcomes of autologous stem cell transplantation in Waldenström’s macroglobulinemia (2019) (6)
- Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes (2020) (6)
- Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors (2017) (6)
- Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis (2019) (6)
- Rapid Engraftment of Neutrophils and Platelets with Mesenchymal Stem Cell Based Cord Blood (CB) Expansion (EXP). (2009) (6)
- Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome (2021) (6)
- Haploidentical transplants for patients with relapse after the first allograft (2020) (6)
- Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2016) (6)
- Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults. (2021) (6)
- Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. (2011) (6)
- Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. (2004) (6)
- Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. (2017) (6)
- Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2 (2021) (6)
- Long‐term durable efficacy of autologous stem cell transplantation in POEMS syndrome (2018) (6)
- Optimizing the Conditioning Regimen for HCT in Myelofibrosis: Long-term Results of a Prospective Phase II Clinical Trial. (2020) (6)
- Central Nervous System Relapse In Adults With Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (2013) (6)
- Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy (2020) (6)
- Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience, (2011) (6)
- A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. (2008) (6)
- Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. (2020) (5)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy (2021) (5)
- Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation (2021) (5)
- Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab (2022) (5)
- Pre-MEASURE: Multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission. (2022) (5)
- 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor (2020) (5)
- Influence of the Intensity of the Allogeneic Conditioning Regimen on the Risk of Hemorrhagic Cystitis (HC) in Patients Receiving Post- Transplant Cyclophosphamide (PT-Cy) As Gvhd Prophylaxis (2019) (5)
- Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel) (2010) (5)
- Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. (2021) (5)
- Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. (2009) (5)
- Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis (2021) (5)
- Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL) (2011) (5)
- Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. (2007) (5)
- Current Approaches to Philadelphia Chromosome–Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant (2021) (5)
- Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy (2011) (5)
- Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD). (2005) (5)
- Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality (2021) (5)
- Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. (2019) (5)
- The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. (2022) (5)
- Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study (2011) (5)
- Allogeneic transplantation for myelofibrosis: Benefit of dose intensity. (2013) (5)
- Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020. (2020) (5)
- Clofarabine±Fludarabine With IV Busulfan And Allogeneic Stem Cell Transplantation For Relapsed, Refractory Myeloid Leukemia (ML) And MDS (2010) (5)
- Etiologies and Impact of Readmission Rates in the First 180 Days After Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Young Adults (2017) (5)
- Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A New Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. (2005) (5)
- Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial (2019) (4)
- Management of acute leukemias (2015) (4)
- Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation. (2022) (4)
- Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2017) (4)
- DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. (2023) (4)
- Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis (2021) (4)
- Alopecia areata after HLA-identical BMT from an affected, sibling donor (2014) (4)
- Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience (2014) (4)
- Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL). (2005) (4)
- Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC. (2018) (4)
- Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS (2008) (4)
- A unique presentation of acute liver failure from herpes simplex virus hepatitis (2016) (4)
- Haploidentical transplants for patients with graft failure after the first allograft (2020) (4)
- Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports (2016) (4)
- Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study (2019) (4)
- Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to t (2019) (4)
- Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. (2019) (4)
- 540P Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4 (2021) (4)
- Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. (2006) (4)
- Melphalan‐based autologous transplant in octogenarian multiple myeloma patients (2018) (4)
- Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (2011) (4)
- Combining CD 19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies (2010) (3)
- Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial (2020) (3)
- A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation (2010) (3)
- A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin’s lymphomas (2010) (3)
- An Analysis of the Costs Associated with Peripheral Blood Hematopoietic Progenitor Cell Mobilization, Collection and Cryopreservation in Patients with Lymphomas Undergoing Autologous Stem Cell Transplantation (2008) (3)
- KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma (2022) (3)
- 306: Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft-vs-host disease (aGVHD) (2007) (3)
- The Role of Allogeneic Stem Cell Transplantation in the Therapy of Adult Acute Lymphoblastic Leukemia (ALL) (2005) (3)
- Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant (2022) (3)
- Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial (2013) (3)
- Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population (2018) (3)
- Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission (2020) (3)
- Serial frailty assessments following allogeneic stem cell transplant in older adults: A pilot study. (2021) (3)
- Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study (2010) (3)
- The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation (2014) (3)
- IL-7 as a Membrane-Bound Molecule for the Costimulation of Tumor-Specific T Cells. (2009) (3)
- Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies (2011) (3)
- Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (2021) (3)
- Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation. (2005) (3)
- Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors (2022) (3)
- Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults (2020) (3)
- High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies (2011) (3)
- Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation (2021) (3)
- Ex-Utero Plus in Utero Collection of Umbilical Cord Blood (CB) for Banking Yields Higher Total Nucleated Cell Counts (TNC) Compared to Either Procedure Alone (2015) (3)
- Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML (2021) (3)
- Haploidentical transplantation (HaploSCT) with post-transplant cyclophosphamide (PTCy) and melphalan-based conditioning: A retrospective analysis of the first 100 patients treated at MD Anderson Cancer Center. (2014) (3)
- Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance (2021) (3)
- Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL). (2009) (3)
- Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia (2016) (3)
- Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial (2016) (3)
- Myeloablative Timed Sequential Busulfan Is Safe in Older Patients (2014) (3)
- CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia (2022) (3)
- Haploidentical Stem Cell Transplantation for Minorities (2011) (3)
- Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results (2023) (3)
- Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). (2009) (2)
- Modern treatment programs for adults with acute lymphoblastic leukemia (2007) (2)
- 285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors (2020) (2)
- Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas (2013) (2)
- Allogeneic Stem Cell Transplantation for CML in Second Chronic Phase After Blast Crisis in the Tyrosine Kinase Inhibitor Era (2011) (2)
- Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph + ) acute lymphoblastic leukemia (ALL) (2010) (2)
- Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2018) (2)
- High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Th (2022) (2)
- Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. (2014) (2)
- Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy (2022) (2)
- Nonmyeloablative Allogeneic Transplantation in the Imatinib Era: Three Chances To Achieve Molecular Remission in CML. (2007) (2)
- Hematopoietic Cell Transplantation in Myelodysplastic Syndromes (2014) (2)
- Graft loss attributed to possible transfusion‐transmitted ehrlichiosis following cord blood stem cell transplant (2018) (2)
- Symptom Burden of Busulfan + Melphalan Versus Melphalan Alone for Multiple Myeloma (2014) (2)
- Clofarabine (Clo) +/− Fludarabine (Flu) with IV Busulfan (Bu) and Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia (ML) and MDS (2008) (2)
- P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL) (2022) (2)
- Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation (2015) (2)
- Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) Conditioning Regimen (2009) (2)
- Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL). (2010) (2)
- Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia: A CIBMTR Study (2020) (2)
- Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center. (2007) (2)
- Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation (2011) (2)
- Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. (2021) (2)
- Multicenter Study of “off-the-Shelf” Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT) (2012) (2)
- Mycophenolate Mofetil: A Friend or a Foe with PTCy and Tacrolimus Prophylaxis in HLA-Matched donors? (2022) (2)
- Inotuzumab ozogamycin (I0), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL). (2012) (2)
- Impact of Pretransplant Cytogenetics and Marrow Remission Status on Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation Conditioned with Busulfan and Fludarabine (2008) (2)
- High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (2020) (2)
- Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome (2018) (2)
- Very Rapid Production of CAR+ T-Cells upon Non-Viral Gene Transfer Using the Sleeping Beauty System (2016) (2)
- Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (2021) (2)
- Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results (2011) (2)
- Bendamustine in combination with fludarabine and rituximab: A novel nonmyeloablative conditioning for allogeneic stem cell transplantation (AST) in patients with lymphoid malignancies. (2011) (2)
- Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma (2014) (2)
- Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation (2017) (2)
- Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years (2016) (2)
- Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission. (2008) (2)
- Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis (2013) (2)
- Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens (2015) (2)
- Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. (2021) (2)
- Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia (2015) (2)
- Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. (2020) (2)
- Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies (2021) (2)
- Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia (2020) (2)
- Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (2012) (2)
- Anti-HLA Antibodies and Graft Rejection In Hematopoietic Stem Cell Transplantation (2010) (2)
- Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation (2015) (2)
- Toxicity and Early Response after Intravenous (IV) Busulfan (Bu) Plus Melphalan (Mel) Conditioning for Autologous Stem Cell Transplantation (SCT) in Patients (pts) with Multiple Myeloma (MM). (2006) (2)
- Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function. (2009) (2)
- Allogeneic transplantation for myelofibrosis: Final analysis of a prospective study after a median follow up of 5 years. (2015) (2)
- Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered (2020) (2)
- CAR T-Cell Therapies: Overcoming the Challenges and New Strategies (2017) (2)
- Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide. (2022) (2)
- Addition Of Bortezemib To High Dose Melphalan Does Not Improve Response Rate Or Progression-Free Survival (2010) (2)
- CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study (2020) (1)
- Allogeneic Stem Cell Transplantation (Allo-SCT) For Relapsed, Refractory Myeloid Leukemia and Mds Using Clofarabine (Clo) ± Fludarabine (Flu) with IV Busulfan (Bu) As Conditioning Therapy (2009) (1)
- Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia (2016) (1)
- Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma. (2007) (1)
- Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. (2022) (1)
- Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes (2016) (1)
- Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy (2016) (1)
- Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. (2022) (1)
- Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy. (2019) (1)
- High Rate Of De Novo Chronic Graft-Versus-Host (cGVHD) Following Busulfan-Fludarabine Conditioning And Allogeneic Stem Cell Transplantation From A Matched-Sibling Donor (MSD) For AML/MDS (2009) (1)
- Imatinib Maintenance Following Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Philadelphia Chromosome Positive (PH+) Acute Lymphoblastic Leukemia (ALL) (2010) (1)
- Cytokines in the treatment of acute leukemias. (2005) (1)
- Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma (2020) (1)
- Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity‐score matched analysis (2021) (1)
- Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem Cell Transplant (ASCT) in Hodgkin's Lymphoma Patients at High Risk of Post-Transplant Recurrence—Comparison with a Concurrent Matched Cohort (2017) (1)
- Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT) (2019) (1)
- Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. (2012) (1)
- A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma (2022) (1)
- Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival (2011) (1)
- Prolonged neurotoxicity in a lymphoma patient after CD19‐directed CAR T‐cell therapy: A case report and brief review of the literature (2020) (1)
- Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience: Transplant in t(4;14) MM. (2023) (1)
- Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML). (2006) (1)
- Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Older Patients with Active, Relapsed or Refractory (R/R) Acute Myeloid Leukemia Results in Successful and Timely Engraftment Not Related to the Radiation Dose Delivered (2021) (1)
- Mixed Phenotype Acute Leukemia: Patient Outcomes According to the WHO 2008 Classification (2013) (1)
- Outcomes In Patients With Acute Lymphoblastic Leukemia In First Or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted Or Unmodified Allografts: Comparison Of Results At Two Institutions (2013) (1)
- Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease (2020) (1)
- Early Mixed T-Lymphocyte and Myeloid Chimerism Is Predictive of Disease Recurrence Following Allogeneic Stem Cell Transplantation for AML/MDS. (2012) (1)
- PS1541 OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BPDCN (2019) (1)
- Mesenchymal Stromal Cells: The Magic Band-Aid? (2014) (1)
- Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy (2020) (1)
- HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. (2022) (1)
- Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results (2016) (1)
- Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial (2021) (1)
- Selective Reprogramming of Cd19-Specific T Cells With IL-21 and CD28 Signaling for Adoptive Immunotherapy of Acute Lymphoblastic Leukemia (2009) (1)
- Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT) (2016) (1)
- Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS. (2004) (1)
- Treatment of FLT3-ITD Positive AML Relapsing After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) with Sorafenib. (2010) (1)
- Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL). (2017) (1)
- Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS (2016) (1)
- Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+ T Cells Genetically Modified Via Non-Viral Sleeping Beauty S ystem Following Hematopoietic Stem Cell Transplantation (HSCT) (2017) (1)
- Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial (2023) (1)
- Comparison of Allogeneic Hematopoietic Cell Transplantation Outcomes from Younger Matched Unrelated Donor Versus Older Sibling Donor for Acute Myeloid Leukemia (2022) (1)
- Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment (2016) (1)
- A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers. (2018) (1)
- Outcomes and Survival in Hepatitis C Virus Seropositive Lymphoma and Myeloma Patients After Autologous Stem Cell Transplantation: 2075 (2014) (1)
- Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML). (2013) (1)
- EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma. (2012) (1)
- Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (2019) (1)
- Principles of Hematopoietic Stem Cell Transplantation (2019) (1)
- High Throughput Non-Viral Gene Transfer of T Cells by Micro-Electroporators to Generate CD19-Specific Cells for Immediate Infusion (2009) (1)
- T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) (2016) (1)
- Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. (2019) (1)
- Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future (2023) (1)
- Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd (2011) (1)
- Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (2022) (1)
- Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma. (2014) (1)
- Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation (2020) (1)
- Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT). (2007) (1)
- Transplant Outcomes of 9/10 HLA Matched Unrelated Donors (MUD) Treated with Post-Transplant Cyclophosphamide for Prevention of Graft Versus Host Disease (2014) (1)
- Development and Comparison of Limited Sampling Strategies for Pharmacokinetically-Guided High-Dose, Intravenous Busulfan (2009) (1)
- Minimal Residual Disease Detected By Multiparameter Flow Cytometry and Complex Karyotype Are the Major Prognostic Factors for Relapse after HCT (2015) (1)
- 114-P: A dose effect of DPB1 mismatches may increase the risk for graft versus host disease in bone marrow transplatns from unrelated donors of patients with high risk myeloid leukemias (2006) (1)
- Factors associated with allogeneic hematopoietic stem cell transplantation (HSCT) outcomes in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with inotuzumab ozogamicin (InO) versus (v) conventional chemotherapy (C). (2017) (1)
- Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience (2022) (1)
- Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen (2019) (1)
- Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma (2019) (1)
- Pre-MEASURE: FLT3-ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission (2022) (1)
- Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies (2022) (1)
- Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. (2008) (1)
- The Clinical Significance of Human Herpes Virus 6 (HHV-6) Dnaemia in 68 Hematopoietic Cell Transplant Recipients (HSCT) (2014) (1)
- Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT) (2012) (1)
- NaïVe Cd19-Specific T Cells Exhibit Superior Proliferation and Potential for Adoptive Immunotherapy (2012) (1)
- A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT). (2021) (1)
- Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis (2021) (1)
- Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial (2021) (1)
- Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for BPDCN (2020) (1)
- 266: Usefulness of Bronchoscopic Lavage in Intensive Care Unit for Critically Ill Stem Cell Transplant Recipients with Pulmonary Infiltrates (2008) (1)
- Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation (2017) (1)
- Predictors of Outcomes in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors (2018) (1)
- 19: Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma (2007) (1)
- Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission (2016) (1)
- Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience. (2008) (1)
- Safety Of T-Cell Replete Haploidentical Stem Cell Transplantation Using Fludarabine, Melpahalan And Thiotepa Conditioning And High-Dose Post-Transplant Cyclophosphamide (2010) (1)
- 96: Incidence and Factors Influencing Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD) (2008) (1)
- Myelofibrosis and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RISCT). (2007) (1)
- HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT). (2006) (1)
- Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies (2008) (1)
- Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study (2018) (1)
- 278. Next-Generation Non-Viral Gene Transfer to Redirect T-Cell Specificity (2016) (1)
- Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. (2022) (1)
- High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC) (2020) (1)
- Superior Outcomes with Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors In Allogeneic Hematopoietic Stem Cell Transplantation (2010) (1)
- Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. (2021) (1)
- Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation (2015) (1)
- A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS (2019) (1)
- Improved Outcome for Allogeneic Transplantation Performed After January 2000 (2009) (0)
- Toward a cure in relapsed ALL: we must do better (2020) (0)
- A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS (2020) (0)
- Better survival with fludarabine and timed sequential busulfan regimen in older patients with AML/MDS. (2017) (0)
- Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation (2021) (0)
- African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis (2020) (0)
- Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens. (2005) (0)
- Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation (2023) (0)
- Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM). (2005) (0)
- Progress in Novel Cellular Therapy Options for CLL: The MD Anderson Perspective (2016) (0)
- Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H. (2004) (0)
- Utility of Day 14 Bone Marrow Evaluation in Adults with Philadelphia Chromosome-Negative ALL: Relationship with Minimal Residual Disease Status (2016) (0)
- External validation of the HIGH‐2‐LOW model: A predictive score for venous thromboembolism after allogeneic transplant (2022) (0)
- Post-Hematopoietic Stem Cell Transplantation (HSCT) Outcomes in Patients With AML Transplanted Prior to Achieving Platelet Recovery (2009) (0)
- Clinical e ffi cacy of anakinra to mitigate CAR T-cell therapy – associated toxicity in large B-cell lymphoma (2020) (0)
- Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma. (2006) (0)
- Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome (2022) (0)
- Campath-IH Combined with Fludarabine/Cyclophophamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation. (2005) (0)
- Outcome of Patients with Classical Hodgkin Lymphoma (cHL) Relapsing after an Autologous Stem-Cell Transplant (ASCT) (2023) (0)
- Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients with Refractory Large B-Cell Lymphoma (LBCL) (2021) (0)
- Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study (2022) (0)
- A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study (2022) (0)
- Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation (2020) (0)
- Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2017) (0)
- Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma (2008) (0)
- Comparison of Busulfan + Melphalan to Melphalan 200 mg/m2 as Preparative Regimen for Autologous Transplantation in Multiple Myeloma (2012) (0)
- Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation (2009) (0)
- Low Rate of Infusional Toxicity following Expanded Cord Blood Transplantation (2014) (0)
- Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML). (2019) (0)
- Timing of Autologous Stem Cell Transplantation (ASCT) in Patients with Primary Central Nervous System Lymphoma (PCNSL) (2023) (0)
- Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant (2023) (0)
- Comparison of Transplant Outcomes in Patients with Acute Lymphoblastic Leukemia after Haploidentical Transplant with Post-Transplant Cyclophosphamide or Matched Unrelated Donor Transplant (2020) (0)
- The Role of Autologous Stem Cell Transplantation in the Management of Acute Lymphoblastic Leukemia in Adults (2008) (0)
- from allogeneic donors Towards eliminating HLA class I expression to generate universal cells (2013) (0)
- Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies (2014) (0)
- Allo-transplant for older patients with acute lymphoblastic leukemia: does it work? (2015) (0)
- A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma, (2011) (0)
- Use of Palifermin in Allogeneic Stem Cell Transplantation (SCT) for Patients with Acute Lymphoblastic Leukemia (ALL) (2009) (0)
- Determinants of Higher Pre-Apheresis CD34+ Count in Patients Undergoing Autologous Hematopoietic Stem Cell Mobilization (2011) (0)
- A Unique Case of GI GVHD in a 37-year-old Male With AML: 1461 (2017) (0)
- A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) (2021) (0)
- Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma (2022) (0)
- Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types (2020) (0)
- Management of Important Adverse Events Associated with Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (2017) (0)
- Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis (2018) (0)
- Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients (2015) (0)
- High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma (2008) (0)
- Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival. (2008) (0)
- Cloning and sequencing of the 16s rrna gene from treponema pallidum (1992) (0)
- Outcomes Of Allogeneic Stem Cell Transplantation for Patients With Acute Leukemia Transformed from Myelofibrosis (2009) (0)
- 296: Etanercept as salvage therapy for chronic graft-versus-host disease (2007) (0)
- Running title: HLA-A disruption in donor cells (2017) (0)
- Hematopoietic cell transplants for BCR/ABL negative acute lymphocytic leukemia (2017) (0)
- Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS. (2008) (0)
- Contents Vol. 132, 2014 (2014) (0)
- Younger Matched Unrelated Donors Confer a Decreased Relapse Risk As Compared to Older Sibling Donors for Adult B-Cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (2022) (0)
- Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation (2018) (0)
- The Incidence and Natural History of Pure Red Cell Aplasia in Major ABO Mismatched Hematopoietic Stem Cell Transplantation in Patients Receiving Modern Reduce Intensity and Reduced Toxicity Regimens (2011) (0)
- Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients (2014) (0)
- A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma. (2007) (0)
- Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome (2013) (0)
- Treating adults with acute lymphoblastic leukemia: it is time to grow up (2013) (0)
- Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation (2019) (0)
- Reduced Intensity Conditioning (RIC) Regimen Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients (PTS) With Acute Lymphoblastic Leukemia (ALL) (2009) (0)
- Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies. (2009) (0)
- Proton Versus Photon Craniospinal Irradiation for Hematologic Malignancies Involving the CNS: Effectiveness and Toxicity in the Setting of Stem Cell Transplant (2016) (0)
- A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation (2022) (0)
- PHASE II TRIAL OF GVHD PROPHYLAXIS WITH POSTTRANSPLANTATION CYCLOPHOSPHAMIDE FOLLOWING REDUCED-INTENSITY BUSULFAN/FLUDARABINE (BU/FLU) CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES (2016) (0)
- Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin’s Lymphomas (NHLs). (2007) (0)
- CT-046: Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study (2021) (0)
- PS1564 HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH DETECTABLE DISEASE AT TRANSPLANT (2019) (0)
- Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR) (2019) (0)
- T Cells Demonstrate Enhanced Specificity for CD19 + Malignancies When Stimulated with IL-21. (2008) (0)
- Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients. (2019) (0)
- Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (2021) (0)
- Long-Term Outcomes after Autologous Stem Cell Transplant (ASCT) for Primary Central Nervous System Lymphoma (PCNSL) (2023) (0)
- Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies. (2023) (0)
- 392: Fundamental nursing responsibilities in mesenchymal stem cell infusion (2007) (0)
- MLL-Rearranged AML Is Associated with Poor Outcomes As Compared to Patients with Intermediate- and Adverse-Risk Disease: A CIBMTR Study of 3779 Adult Patients (2020) (0)
- Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant (2023) (0)
- The role of allogeneic stem cell transplantation in the therapy of adult acute lymphoblastic leukemia O papel do transplante alogênico de células progenitoras na terapia de leucemia linfoblástica aguda em adultos (2005) (0)
- Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Stud (2020) (0)
- Impact of Maintenance Therapy in High-Risk Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation (2018) (0)
- Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning (2013) (0)
- Novel Re-Induction and Anti-CD45 Targeted Conditioning with Iodine ( 131 I) Apamistamab [Iomab-B] Yields Encouraging Results in Older Patients with Active, Relapsed or Refractory AML (R/R AML): Safety & Feasibility Data from the Prospective Randomized Phase III Sierra Trial (2019) (0)
- Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting (2020) (0)
- Predictors of Veno-Occlusive Disease (VOD) of the Liver in Patients Treated with Inotuzumab Ozogamicin (InO) Containing Regimen in B-Cell Acute Lymphoblastic Leukemia (2022) (0)
- Impact of Donor Age in Haploidentical-PTCy Versus MUD-PTCy HCT in AML patients. (2023) (0)
- Hematopoietic Cell Transplant-Composite Risk (HCT-CR) — a Novel Prognostic Model to Predict Transplant Outcomes (2018) (0)
- Captisol-Enabled Melphalan (Evomela) Pharmacokinetics between Short and Long Infusion Arms in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation (2022) (0)
- Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL) (2020) (0)
- A Phase II Clinical Trial of "Off-the-Shelf" NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies (2022) (0)
- 779TiP Commencement of first-in-human phase I/II TCR-T clinical trial targeting shared tumor-specific hotspot mutations in solid tumors (2022) (0)
- Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial (2020) (0)
- MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. (2022) (0)
- Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS (2011) (0)
- Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (2012) (0)
- Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation (2016) (0)
- Co-Morbidity Score at the Time of Transplant Determines Prognosis in Older Patients Who Develop Acute Graft-Vs.-Host Disease (GVHD). (2009) (0)
- Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis (2020) (0)
- Transplant Outcomes for TP53 AML and MDS in a Contemporary Era (2022) (0)
- Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia (2013) (0)
- Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis (2022) (0)
- Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2003) (0)
- Poster: CT-046: Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study (2021) (0)
- Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas (2016) (0)
- CLINICAL IMPLICATIONS OF CYTOPENIAS BEYOND DAY 30 AFTER AXI‐CEL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (2019) (0)
- Idiopathic Portal Hypertension Related Refractory Ascites (IPHRA) after Allogeneic Stem Cell Transplant (2019) (0)
- High-dose versus standard-dose rituximab with BEAM in autologous stem cell transplantation (SCT) for relapsed aggressive b-cell non-Hodgkin’s lymphomas (NHL). (2016) (0)
- Myeloablative Conditioning Using Timed Sequential Busulfan in Older Patients with Acute Myeloid Leukemia: Long Term Results of a Prospective Phase II Clinical Trial (2019) (0)
- Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial (2021) (0)
- The Impact of Pre-Transplant Valganciclovir on Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplant (2012) (0)
- Mesenchymal stem cells as therapy for graft versus host disease: What have we learned? (2013) (0)
- Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen (2020) (0)
- Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival (2017) (0)
- Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics, and Pharmacodynamics Initial Findings from a Phase 1/2 Study (2023) (0)
- Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond (2022) (0)
- Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. (2023) (0)
- Issue information (2015) (0)
- Faster Lymphocyte Recovery After Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts For Decreased Non-Relapse Mortality (NRM) In Adults With Acute Lymphoblastic Leukemia (ALL) (2010) (0)
- Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia (2016) (0)
- Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia (2018) (0)
- Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2019) (0)
- Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival (2017) (0)
- Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy (2022) (0)
- P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA (2022) (0)
- Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation (2019) (0)
- Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma (2015) (0)
- Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing First Autologous Hematopoietic Stem Cell Transplant (2023) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia (2019) (0)
- Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors (2019) (0)
- List of Contributors (2019) (0)
- Sequential Therapy With Nonablative Allogeneic Stem Cell Transplantation, Post Transplant Imatinib and Donor Lymphocyte Infusion for Chronic Myeloid Leukemia (2009) (0)
- Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy (2022) (0)
- Continuing Improvement in the Outcome of Patients with Multiple Myeloma Undergoing Auto-HCT Over Three Decades (2018) (0)
- Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy (2010) (0)
- Current Approach to Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (2021) (0)
- Immune Reconstitution Following Tisagenlecleucel in Pediatric, Adolescent and Young Adult (AYA) Patients with Relapsed Refractory (R/R) B Acute Lymphoblastic Leukemia (B ALL) (2022) (0)
- Does Cell of Origin Classification Impact Outcomes in Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplant (2019) (0)
- 20: Autologous stem cell transplantation for elderly patients with multiple myeloma (2007) (0)
- Inferior Outcome With Addition Of Rituximab For Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Acute Lymphoblastic Leukemia (ALL) (2009) (0)
- A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL (2017) (0)
- Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma. (2009) (0)
- Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types (2018) (0)
- Internal and External Validation of the High-2-Low Model: A Predictive Score for Venous Thromboembolism after Allogeneic Transplant (2021) (0)
- Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer (2021) (0)
- Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT) (2021) (0)
- Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation. (2007) (0)
- Washout Time to Avoid Drug-Drug Interaction between Blinatumomab and Busulfan during Hematopoietic Stem Cell Transplant Conditioning (2022) (0)
- Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant (2023) (0)
- Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies (2010) (0)
- Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. (2006) (0)
- Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study (2020) (0)
- Comparison of Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) with Beam and Busulfan/Melphalan (Bu/Mel) in Concurrent Cohorts of Refractory Hodgkin'S Lymphoma (HL) Patients Receiving an Autologous Stem-Cell Transplant (2012) (0)
- Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation (2020) (0)
- Relevance and Factors Predicting for Early Lymphocyte Recovery After Allogeneic Bone Marrow Stem Cell Transplantation (BMT). (2012) (0)
- HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT (2022) (0)
- Assessing Sleeping Beauty Transpositions for T-Cell Immunotherapy by Supercomputer-Based High-Throughput Profiling of Integration Events (2012) (0)
- AML-317: Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia (2020) (0)
- Fludarabine with Myeloablative Timed-Sequential Busulfan in Older Patients: Results of a Randomized Phase II Clinical Trial (2019) (0)
- Intravenous (i.v.) busulfan (Bu) plus melphalan (Mel) is a well-tolerated preparative regimen for stem cell transplantation (SCT) in patients (pts) with advanced lymphoid malignancies. (2005) (0)
- Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML (2015) (0)
- PS1389 IMPACT OF DIFFERENT MAINTENANCE THERAPY OPTIONS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA AT MD ANDERSON CANCER CENTER (2019) (0)
- Development and validation of a patient‐reported outcome measure to assess symptom burden after chimeric antigen receptor T‐cell therapy (2023) (0)
- Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance (2020) (0)
- Autologous stem cell transplantation in dialysis-dependent myeloma patients. (2014) (0)
- Debate: Transplant is Still Necessary in the Era of Targeted Cellular Therapy for ALL (2019) (0)
- Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function. (2022) (0)
- Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission (2022) (0)
- Comparison of Allogeneic Hematopoietic Cell Transplantation Outcomes from Younger Matched Unrelated Donor Versus Older Sibling Donor for Older Adults with AML (2023) (0)
- Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy (2021) (0)
- Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. (2021) (0)
- Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes (2021) (0)
- Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study (2022) (0)
- Impact of Induction with VRD Vs. VCD on the Outcome of Patients with Multiple Myeloma after an Autologous Hematopoietic Stem Cell Transplantation (2021) (0)
- Impact of Cytogenetics and Marrow Remission Status on Disease Progression in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Allogeneic Stem Cell Transplantation (2009) (0)
- Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT) (2013) (0)
- KRD vs. VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Newly Diagnosed Multiple Myeloma (2022) (0)
- Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART) (2022) (0)
- The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL) (2020) (0)
- Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies (2020) (0)
- The impact of peri-transplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation (2017) (0)
- The use of geriatric assessment to predict frailty after allogeneic stem cell transplantation (2014) (0)
- Long-Term Outcomes of Multiple Myeloma Patients Treated with VRD Induction, Autologous Hematopoietic Cell Transplantation with Melphalan 200 mg/m2 Conditioning, and Lenalidomide Maintenance (2021) (0)
- Impact of Smoking on Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation (2023) (0)
- PHASE II TRIAL OF HIGH-DOSE GEMCITABINE/BUSULFAN/MELPHALAN WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PRIMARY REFRACTORY OR POOR-RISK RELAPSED HODGKIN’S LYMPHOMA (2021) (0)
- Allogeneic Stem Cell Transplantation for CML Resistant to Tyrosine Kinase Inhibitors (2011) (0)
- Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS (2008) (0)
- Treatment of AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Low-Dose Azacitidine (AZA). (2010) (0)
- High Rate of Engraftment and Low Regimen-Related Toxicity Using Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation (2008) (0)
- Phase I/II Trial of Lenalidomide and High-Dose Melphalan As Preparative Regimen for Relapsed Myeloma (2014) (0)
- Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial (2021) (0)
- Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning in Older Patients with Myelodysplastic Syndromes (2016) (0)
- Long-term Outcomes After Treatment with Clofarabine ± Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS (2016) (0)
- A Randomized Phase III Trial Of Busulfan + Melphalan (Bu-Mel) Vs Melphalan Alone For Multiple Myeloma: Longer PFS In The Bu-Mel Arm (2015) (0)
- Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database (2019) (0)
- Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study (2018) (0)
- Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients (2023) (0)
- 110-P: Donor-Specific (DSA) Anti-DP Antibodies Associate With Graft Failure (PGF) in Unrelated Donor Hematopoietic Stem Cell Transplantation (MUDHSCT) (2010) (0)
- PS1530 POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY (2019) (0)
- High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin’s Lymphoma (NHL) in Patients over 65 Years of Age. (2006) (0)
- The Role Of Donor-Specific Anti-HLA Antibodies (DSA) In Hematopoietic Stem Cell Transplantation From Matched Unrelated Donors (2010) (0)
- Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience (2020) (0)
- Advances in Cellular Immunotherapy in Hematologic Malignancies (2021) (0)
- Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS (2023) (0)
- Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study (2022) (0)
- Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR) (2013) (0)
- Creatinine Clearance Is Associated with Propylene Glycol-Free Melphalan (Evomela) Pharmacokinetics and Gastrointestinal Toxicities in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation (2023) (0)
- Myeloablative Timed Sequential Busulfan Is Safe in Patients With Relapsed or High-Risk Multiple Myeloma (2015) (0)
- Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. (2020) (0)
- Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation (2018) (0)
- A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma (2021) (0)
- Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia Transformed from Myelofibrosis (2008) (0)
- Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation (2023) (0)
- Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. (2022) (0)
- Minimal Residual Disease (MRD) Assessed By Multi-Parameter Flow Cytometry (MFC) Is Highly Predictive of Outcome in Adult Patients with Acute Lymphoblastic Leukemia (ALL) (2014) (0)
- Immediate Adverse Events Following infusion of ex vivo-Expanded Cord Blood for Stem Cell Transplantation (2011) (0)
- Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens (2011) (0)
- Obesity Does Not Impact Outcome in Patients with AML/MDS Undergoing Allogeneic Transplantation. (2007) (0)
- Philadelphia Chromosome -P ositive Acute Lymphoblastic Leukemia (2009) (0)
- Outcomes of second allogeneic hematopoietic stem cell transplantation (SCT) for patients with acute lymphoblastic leukemia (ALL). (2012) (0)
- Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL) (2015) (0)
- Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors (2011) (0)
- Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease and Prognostic Factors at the MD Anderson Cancer Center (MDACC) (2015) (0)
- Large scale generation of genetically modified T-cells using micro-electroporators for cancer treatments (2009) (0)
- Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). (2009) (0)
- Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis (2022) (0)
- The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT) (2013) (0)
- Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson (2019) (0)
- Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia (2018) (0)
- Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type (2023) (0)
- Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse (2020) (0)
- Poster: MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (2022) (0)
- The Role of Hematopoietic Stem‐Cell Transplantation in Adults with Acute Lymphoblastic Leukemia (2011) (0)
- CD19-Specific T Cells for Treatment of Pediatric Acute Lymphocytic Leukemia Using Sleeping Beauty Transposition. (2007) (0)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Blastic Plasmacytoid Dendritic Cell Neoplasm: A CIBMTR Analysis (2022) (0)
- Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. (2023) (0)
- Chimeric Antigen Receptor T Therapy for Adult B-Cell Acute Lymphoblastic Leukemia: State-of the-(C)ART and Road Ahead. (2023) (0)
- A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab (2020) (0)
- Ph-Positive ALL Patients Who Are Treated with Tyrosine Kinase Inhibitors Have Similar Post-Transplant Survival As Ph-Negative Patients (2023) (0)
- Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors (2011) (0)
- P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB (2022) (0)
- Conditioning with Busulfan Plus Melphalan (Bu-Mel) Results in More Prolonged Progression-Free Survival (PFS) Versus Melphalan (Mel) Alone before Autologous Stem Cell Transplantation (auto-HCT) in Patients with High-Risk Multiple Myeloma (MM): Long-Term Results of a Randomized, Phase 3 Trial (2020) (0)
- Assessing Potential Genotoxicity of Sleeping Beauty Transposition Events in T-Cell Immunotherapy by Supercomputer-Based High Throughput Profiling, (2011) (0)
- Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma (2006) (0)
- Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients (2017) (0)
- Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation (2021) (0)
- Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30 (2022) (0)
- Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Party (ALWP) of the European (2018) (0)
- Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response (2021) (0)
- ASCT vs CART for Patients with Relapsed LBCL in PR: Role of TMTV. (2023) (0)
- Outcome of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma (2016) (0)
- Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse (2012) (0)
- Second Allogeneic Transplants for Relapsed Acute Lymphoblastic Leukemia Result in High Response Rates of Short Duration: Further Intervention Is Required to Maintain Response. (2009) (0)
- Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant (2013) (0)
- The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL). (2005) (0)
- Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy (2014) (0)
- Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (2022) (0)
- Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial (2022) (0)
- Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. (2009) (0)
- Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL) (2008) (0)
- Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression (2019) (0)
- Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma (2012) (0)
- Development and validation of a novel disease risk model for patients with AML receiving allogeneic hematopoietic cell transplantation. (2019) (0)
- Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results (2015) (0)
- Long-term survival of patients with AML in remission after reduced intensity allogeneic hematopoietic stem cell transplantation (RISCT) (2007) (0)
- Single-Agent Lenalidomide Maintenance after Upfront Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma: The MD Anderson Cancer Center Experience (2023) (0)
- An Analysis of the Charges Associated With Peripheral Blood Hematopoietic Progenitor Cell (HPC) Mobilization, Collection and Cryopreservation In Patients With Lymphomas Undergoing Autologous Stem Cell Transplantation (2009) (0)
- Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma (2020) (0)
- Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML (2008) (0)
- Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy (2020) (0)
- A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants. (2007) (0)
- Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience (2015) (0)
- Peri-Stem Cell Transplant Toxicity after Craniospinal Irradiation: The Influence of Timing (2018) (0)
- Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy (2021) (0)
- Clofarabine ± Fludarabine with IV Busulfan and Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS (2014) (0)
- Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia (2023) (0)
- Salvage autologous transplantation in multiple myeloma (2006) (0)
- Effect of Timing and Duration of Maintenance Lenalidomide in Myeloma Patients after Autologous Stem Cell Transplantations (2014) (0)
- P367: LONG TERM OUTCOMES OF NEWLY DIAGNOSED CRLF2 REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (2022) (0)
- Graft-Versus-Host Disease Following Radiation Therapy in Patients With a History of Allogeneic Stem Cell Transplant (2015) (0)
- 15. Evaluation of Retained Immunity for Tetanus-Diphtheria and Pneumococcal Vaccines in Recipients of Cellular Therapies (2021) (0)
- International Consensus Criteria for Tyrosine Kinase Inhibitor Response and Outcome of Allogeneic Stem Cell Transplantation for CML (2012) (0)
- Complex Karyotype and Low Hypodiploidy/Near Triploidy are Adverse Prognostic Factors in Adult ALL (ALL) Independent of MRD Status (2016) (0)
- AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial (2020) (0)
- Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation (2020) (0)
- Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Partow Kebriaei?
Partow Kebriaei is affiliated with the following schools:
